

Project Title	Funding	Strategic Plan Objective	Institution
PRECURSORS TO THE DEVELOPMENT OF ANXIETY DISORDERS IN YOUNG CHILDREN WITH AUTISM SPECTRUM DISORDER	\$589,750	Q2.S.E	Duke University
PRECURSORS TO THE DEVELOPMENT OF ANXIETY DISORDERS IN YOUNG CHILDREN WITH AUTISM SPECTRUM DISORDER	\$515,246	Q2.S.E	University of North Carolina at Chapel Hill
Treatment of medical conditions among individuals with autism spectrum disorders	\$488,568	Q2.S.E	National Institutes of Health
Early life seizures disrupt critical period plasticity	\$429,559	Q2.S.E	University of Pennsylvania
Refining the Tourette Syndrome phenotype across diagnoses to aid gene discovery	\$417,271	Q2.Other	University of California, San Francisco
Selective disruption of hippocampal dentate granule cells in autism: Impact of PT	\$396,897	Q2.S.E	Cincinnati Children's Hospital Medical Center
Neuroendocrine regulation of metabolism and neurocognition	\$355,088	Q2.S.E	National Institutes of Health
Molecular mechanisms linking early life seizures, autism and intellectual disability	\$313,576	Q2.S.E	University of Colorado Denver
Self-Regulation and Sleep in Children At Risk for Autism Spectrum Disorders	\$249,000	Q2.S.E	Purdue University
IMAGING DEPRESSION IN ADULTS WITH ASD	\$192,601	Q2.S.E	State University New York Stony Brook
PRECURSORS TO THE DEVELOPMENT OF ANXIETY DISORDERS IN YOUNG CHILDREN WITH AUTISM SPECTRUM DISORDER	\$173,826	Q2.S.E	Duke University
Characterization of the sleep phenotype in adolescents and adults with autism spectrum disorder	\$150,000	Q2.S.E	Vanderbilt University
Molecular analysis of gene-environment interactions in the intestines of children with autism	\$150,000	Q2.S.E	Columbia University
Direct recording from autism brains	\$120,148	Q2.S.E	California Institute of Technology
Platform for autism treatments from exome analysis	\$100,000	Q2.S.E	Rockefeller University
AUTISM AND OBESITY: CO-OCCURRING CONDITIONS OR DRUG SIDE EFFECTS?	\$99,820	Q2.S.E	Children's Mercy Hospital
CIRCADIAN RHYTHMS IN CHILDREN WITH ASD AND THEIR INFANT SIBLINGS	\$99,000	Q2.S.E	Naval Medical Research Center
Characterizing sleep disorders in autism spectrum disorder	\$75,107	Q2.S.E	Stanford University
Testing the ribosomal protein S6 as treatment target and biomarker in autism spectrum disorders	\$60,000	Q2.S.D	Cincinnati Childrens Hospital Medical Center
Single-unit recordings in neurosurgical patients with autism	\$56,900	Q2.S.E	California Institute of Technology
Assessing sleep regulation, sleep-dependent memory consolidation, and sleep-dependent synaptic plasticity in mouse genetic models of schizophrenia and autism spectrum disorders	\$32,469	Q2.S.E	University of Pennsylvania
Role of astrocytic glutamate transporter GLT1 in Fragile X	\$5,000	Q2.S.D	Tufts University

Project Title	Funding	Strategic Plan Objective	Institution
The effects of disturbed sleep on sleep-dependent memory consolidation and daily function in individuals with ASD	\$0	Q2.S.E	Beth Israel Deaconess Medical Center
The role of mTOR inhibitors in the treatment of autistic symptoms in symptomatic infantile spasms	\$0	Q2.S.E	Albert Einstein College of Medicine of Yeshiva University
Salivary melatonin as a biomarker for response to sleep interventions in children with autism	\$0	Q2.S.E	University of Colorado Denver

